Geneesmiddelen | Horizonscan geneesmiddelen

Masitinib

Olopatadine / mometasone

Andexanet alfa Betrixaban Ciraparantag Dabigatran etexilaat Rivaroxaban

Benralizumab Dupilumab Tiotropium Tralokinumab

Amoxicilline / omeprazol / rifabutin Cadazolid Eravacycline Iclaprim Imipenem / Relebactam Liposomaal amikacine Meropenem / vaborbactam Nemonoxacin Omadacycline Ozenoxacine

Atezolizumab Durvalumab Durvalumab / Tremelimumab Ramucirumab

Alicaforsen

Pouchitis Ulcerative colitis

Darvadstrocel

Etrolizumab

Ulcerative colitis Ziekte van Crohn

Masitinib Remestemcel-L Rifaximin Tenapanor Tofacitinib Ustekinumab

Brain cancer vaccine Depatuxizumab mafodotin

Abemaciclib Atezolizumab Neratinib Olaparib Pembrolizumab Pertuzumab

Ribociclib

Breast cancer, advanced metastatic, HR+ and HER2-, in combination with fulvestrant, postmenopausal women and men, 1L en 2L. Breast cancer, advanced metastatic, HR+ and HER2-, in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin, premenopausal women.

Talazoparib Veliparib

Benralizumab Fluticasone furoate / umeclidinium (bromide) / vilanterol (trifenatate) Formoterol / glycopyronium / budesonide Glycopyrrolate / formoterol Mepolizumab Revefenacin

Avacopan

Atezolizumab Nivolumab

Ivacaftor Tezacaftor / ivacaftor

Leuco-methylthioninium

Alzheimer’s disease, mild-to-moderate. Dementia, behavioural variant frontotemporal.

Dapagliflozine Empagliflozine Ertugliflozin Ertugliflozin / metformin Ertugliflozin / sitagliptin

Exenatide

Diabetes type 2 Diabetes type 2

Glibenclamide Semaglutide Sotagliflozin

Vigabatrin

Brolucizumab Cenegermin

Ciclosporin

Keratoconjunctivitis sicca (or dry eye disease), moderate-to-severe and specifically in patients with atopic keratoconjunctivitis. Treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.

Eculizumab

KPI-121

Dry eye disease. Ocular pain and inflammation. Om te gebruiken na oogchirurgie.

Latanoprostene bunod Lifitegrast Mercaptamine RGN-259 Voretigene neparvovec

Ibrutinib Itacitinib

Afatinib Brilacidin

Durvalumab

Squamous cell carcinoma of the head and neck, 1L PDL 1. Squamous cell carcinoma of the head and neck, 2L

Durvalumab / Tremelimumab

Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L Durvalumab monotherapy in PDL1-positive tumours or in combination with Tremelimumab for PDL1-negative tumours. Squamous cell carcinoma of the head and neck, 1L PDL 1

Pembrolizumab

Eptinezumab Erenumab Fremanezumab

Galcanezumab

Prophylactic treatment of migraine headache. Clusterhoofdpijn

Lasmiditan

Donor-derived T-lymphocyte enriched leukocyte preparation depleted ex vivo of host-alloreactive T cells.

Fedratinib

Myelofibrosis Polycythemia vera

Lusutrombopag Pacritinib Romiplostim Ropeginterferon alfa-2b Treosulfan

Damoctocog alfa pegol

Emicizumab

Hemlibra is geïndiceerd voor de routineprofylaxe van bloedingen bij patiënten met hemofilie A met remmers tegen factor VIII. Hemlibra kan bij alle leeftijdsgroepen worden gebruikt. Hemlibra is geïndiceerd voor de routinematige profylaxe van bloedingen bij patiënten met hemofilie A zonder remmers tegen factor VIII.

Eptacog beta (activated) Rurioctocog alfa pegol Vonicog alfa

Abaloparatide Elagolix Enclomifene Glucagon Macimorelin Osilodrostat Prasterone Recombinant parathyroid hormone Tenapanor

Atezolizumab Avelumab Ipilimumab Rocapuldencel-T Sunitinib

Blinatumomab

Adults with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL). Relapsed / Refractory Ph+ Adult Acute Lymphoblastic Leukemia (ALL). Relapsed / Refractory precursor-B Acute Lymphoblastic Leukemia (ALL) in children.

Bosutinib Cytarabine / daunorubicin (liposomaal)

Dasatinib

Indicated for the treatment of paediatric patients with newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. Pediatric ALL

Duvelisib Enasidenib Eryaspase (Asparaginase) Gemtuzumab ozogamicin Gilteritinib

Ibrutinib

1L Chronic Lymphatic Leukemia young and fit patients Chronische Lymfatische Leukemie 1L, non-fit icm obinutuzumab

Idelalisib Imetelstat Inotuzumab ozogamicin Sapacitabine Tamibarotene Tisagenlecleucel-T Venetoclax / cytarabine Venetoclax in combinatie met rituximab

Alirocumab Evolocumab Volanesorsen (sodium)

Cabozantinib Nivolumab Ramucirumab

Obeticholic acid

Atezolizumab

Tecentriq is als monotherapie geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderde of gemetastaseerde niet-kleincellige longkanker (NSCLC) na eerdere behandeling met chemotherapie. Patiënten met EGFR-activerende mutaties of ALK-positieve mutaties moeten ook doelgerichte behandeling hebben ontvangen voor ze Tecentriq krijgen. First line treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Combination of Tecentriq, Avastin and chemotherapy. For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy

Avelumab Brigatinib

Durvalumab

Non-small cell lung cancer (NSCLC) stage III, unresectable. Non-small cell lung cancer (NSCLC), 1L monotherapy

Durvalumab / Tremelimumab Lorlatinib Lurbinectedin Osimertinib Rociletinib Rovalpituzumab tesirine Veliparib

Axicabtagene ciloleucel Brentuximab vedotin

Ibrutinib

Follicular lymphoma (FL), relapsed / refractory. Mantle cell lymphoma (MCL), 1L. Marginal zone lymphoma (MZL), relapsed / refractory. Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL), 1L. Waldenstrom's macroglobulinemia (WM) in combinatie met Rituximab

Lenalidomide / Rituximab Mogamulizumab Tisagenlecleucel-T

Nintedanib Nivolumab

Asfotase alfa Burosumab Cerliponase alfa Chenodeoxycholzuur Cyclodextrine (Hydroxypropyl betadex) Ibiglustat Idursulfase-IT Kaliumcitraat / kaliumwaterstofcarbonaat Metreleptin Neod001 Patiromer Pegvaliase Sebelipase alfa Sodium benzoate Sodium zirconium cyclosilicate Velmanase alfa Vestronidase alfa

Carfilzomib

Daratumumab

Multipel myeloom frontline behandeling in combinatie met Rd, non fit voor ASCT. Multipel myeloom frontline behandeling in combinatie met VMP non fit voor ASCT. Multipel myeloom frontline behandeling voor ASCT in combinatie met VTD.

Denosumab Lenalidomide / bortezomib / dexamethason Plitidepsin Pomalidomide / bortezomib / dexamethason

ALKS8700 Cladribine Masitinib

Ocrelizumab

Volwassen patiënten met actieve relapsing multiple sclerose (RMS) die is gedefinieerd door klinische of beeldvormende kenmerken. Volwassen patiënten met vroege primair progressieve multiple sclerose (PPMS) gebaseerd op de ziekteduur, mate van invaliditeit en beeldvormende kenmerken die typerend zijn voor ontstekingsactiviteit.

Ozanimod Siponimod

Adeno-associated viral vector serotype 9 containing the human SMN gene (AVXS-101)

Botulinum A toxin

Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI). Lower limb spasticity (LLS), post stroke.

Eteplirsen Ibudilast Idebenone Mexiletine HCl Nusinersen Valbenazine

Lutetium (177Lu) oxodotreotide Selumetinib Telotristat etiprate

Budesonide Forigerimod (Rigerimod) Lanadelumab Lesinurad / allopurinol Tocilizumab Triamcinolone

Isavuconazole

Alpha-1 antitrypsin Mepolizumab Nintedanib Pirfenidone Rituximab Sirolimus

Allogenic immunomodulatory progenitor cells Canakinumab Ticagrelor Valsartan / sacubitril

Romosozumab

Botulinum A toxin CM-AT / CM-4612 Esketamine Inotersen Patisiran

Avatrombopag Caplacizumab Ferumoxytol Rivipansel Sodium

Entolimod Larotrectinib Pembrolizumab

Avelumab Niraparib (tosylate monohydrate)

Olaparib

Lynparza is geïndiceerd als monotherapie voor de onderhoudsbehandeling van volwassen patiënten met platinasensitief recidief hooggradig epitheliaal ovarium, tuba- of primair peritoneaal carcinoom die een respons (volledige of partiële) vertonen op platinabevattende chemotherapie. BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Olaparib / Cediranib Rucaparib Veliparib

Oxycodon ER

Olaparib

Pimavanserin

Apalutamide

Chemo-naieve gemetastaseerde castratie resistente prostaat carcinoom, in combinatie met Abiraterone. Gemetastaseerde hormoon-gevoelige, hoog-volume prostaat carcinoom. Niet-gemetastaseerde castratie resistente prostaat carcinoom.

Darolutamide

Enzalutamide

Adult men with newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen depreviation therapy. Niet gemetastaseerde castratieresistente prostaatkanker (M0CRPC).

Olaparib Padeliporfin

Brexpiprazole

Cariprazine

Schizofrenie bij volwassenen. Bipolaire depressie

Esketamine Lurasidone

Infliximab SC

Ixekizumab

Alleen of in combinatie met methotrexaat geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten die één of meer therapieën met disease-modifying antirheumatic drugs (DMARDs) niet verdroegen of daar ontoereikend op reageerden. Axiale Spondyloartritis

Tofacitinib Upadacitinib

Binimetinib Cemiplimab Dabrafenib / Trametinib Encorafenib LN-144 (TIL) Nivolumab Pembrolizumab

Bimekizumab Certolizumab pegol

Dupilumab

Dupixent is geïndiceerd voor de behandeling van matig-ernstige tot ernstige atopische dermatitis bij volwassenen die in aanmerking komen voor een systemische behandeling. Atopische dermatitis bij kinderen

Guselkumab Nemolizumab Risankizumab Tildrakizumab Tralokinumab Ustekinumab

Melatonin Pitolisant Tasimelteon

Atezolizumab Masitinib Nivolumab Pembrolizumab

Bictegravir / emtricitabine / tenofovir alafenamide fumaraat CMV DNA vaccin (ASP0113) Dolutegravir / rilpivirine Doravirine Doravirine / lamivudine / tenofovir disoproxil (fumarate) Fostemsavir Letermovir Peramivir Recombinant zoster vaccin Sofosbuvir / velpatasvir / voxilaprevir Zanamivir

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.

Published on 12 June 2018

ALS

Allergy

Antithrombotic medications

Asthma

Bacterial infections

Bladder cancer

Bowel diseases

Alicaforsen

Etrolizumab

Brain cancer

Breast cancer

Ribociclib

COPD

Cardiovascular diseases

Colon cancer

Cystic fibrosis

Dementia

Leuco-methylthioninium

Diabetes

Exenatide

Epilepsy

Eye disorders

Ciclosporin

KPI-121

Graft versus Host

Head and neck cancer

Durvalumab

Durvalumab / Tremelimumab

Headache

Galcanezumab

Hematology other

Fedratinib

Hemostasis promoting medication

Emicizumab

Hormonal disorders

Kidney cancer

Leukemia

Blinatumomab

Dasatinib

Ibrutinib

Lipid-lowering medications

Liver cancer

Liver diseases

Lung cancer

Atezolizumab

Durvalumab

Lymphoma

Ibrutinib

Mesothelioma

Metabolic diseases

Multiple Myeloma

Daratumumab

Multiple sclerosis

Ocrelizumab

Muscular diseases

Botulinum A toxin

Neuroendocrine cancer

Other chronic immune diseases

Other infectious diseases

Other lung

Other medication for cardiovascular diseases

Other metabolism and Endocrinology

Other neurological disorders

Other non-oncological hematological medications

Other oncology

Ovarian cancer

Olaparib

Pain

Pancreatic cancer

Parkinson's

Prostate cancer

Apalutamide

Enzalutamide

Psychiatry

Cariprazine

Rheumatism

Ixekizumab

Skin cancer